APOA1 and injury: However, FGF15/19 has a very short half-life with a high glomerular filtration rate.38 To circunvent this limitation we recently developed a chimaeric molecule based on the fusion of FGF19 with apolipoprotein A-I (ApoA-I) named Fibapo.22 The ApoA-I moiety confers Fibapo increased biological stability, and targets it to the liver through the interaction of the ApoA-I moiety with the hepatocyte's scavenger receptor class B type I.22 Here, we demonstrate the applicability of Fibapo for the treatment of APAP-induced liver injury and in the stimulation of aged liver regeneration.